Here are the latest stories being discussed in biopharma today:

Novartis Hesitates on Cytokinetics Acquisition

Novartis has reportedly pulled back from its suspected acquisition of biotech company Cytokinetics. Though neither company confirmed the discussions, shares in Cytokinetics fell by 20% following news the potential agreement would not proceed. It was expected that Novartis had interest in Cytokinetics’ positive Phase III data for its heart disease program, aficamten, given robust sales forecasts.

FDA: No Link Between GLP-1s and Suicidal Thoughts

The FDA has determined that GLP-1s, a medical treatment for diabetes and obesity, do not lead to suicidal thoughts or actions. The preliminary review was based on clinical trials and safety data. However, the agency stated that the possibility of a small risk cannot be entirely ruled out and further investigation is ongoing.

Biogen Backs Out of Agreement with Acorda

Biogen has ended its license and collaboration agreement with Acorda Therapeutics for multiple sclerosis drug Fampyra. Biogen will return the commercialization rights to Acorda, allowing the latter to take over the distribution and supply of the drug for multiple sclerosis patients outside of the US starting January 1, 2025.

J&J Continues ‘Save Legs’ Campaign

Johnson & Johnson is extending their awareness campaign titled “Save Legs, Change Lives” to focus on Hispanic patients who have higher PAD-related amputation rates. This campaign follows a successful effort in 2023 to focus on areas where Black Americans had higher PAD-related amputation rates.

FDA Building Pilot to Streamline International Gene Therapy Regulations

The FDA aims to make international gene therapy regulations more efficient through a new pilot program. The program is part of the agency’s efforts toward global regulatory harmonization and is backed by the World Health Organization.

Making Better Pharma Ads: Try Humor and More Branding

A new study from Kantar suggests pharmaceutical companies could improve their advertisements by incorporating humor and clear brand images. Even though pharmaceutical ailments are serious, the study suggests there are ways to liven up ads without undermining the gravity of the health issues being addressed.

FDA Mediates French Antibiotics Import To Counter Syphilis Drug Shortage

To alleviate a shortage in Syphilis medications, the FDA has approved the import of French antibiotics.

Gilead’s Lawsuit Over the Delay in Releasing Safer HIV Drug Holds Ground

The case against Gilead Sciences for delaying the release of a safer HIV drug continues to hold strong in court. The pharmaceutical company faces severe backlash for its alleged delay.